38.98
+1.26(+3.34%)
Currency In USD
| Previous Close | 37.72 |
| Open | 38.14 |
| Day High | 39.15 |
| Day Low | 38.14 |
| 52-Week High | 40.47 |
| 52-Week Low | 14.8 |
| Volume | 138,446 |
| Average Volume | 922,370 |
| Market Cap | 2.97B |
| PE | -21.9 |
| EPS | -1.78 |
| Moving Average 50 Days | 27.78 |
| Moving Average 200 Days | 27.1 |
| Change | 1.26 |
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
GlobeNewswire Inc.
Sep 05, 2025 11:00 AM GMT
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month r
CG Oncology Completes Enrollment in PIVOT-006
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guid
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 29, 2025 12:00 PM GMT
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder